I85PREP
⌘ K
PPB Pharmacist Exam study materials
PPB Pharmacist Exam study resources

PPB Pharmacist Exam practice questions

One question at a time. Build your PPB Pharmacist Exam understanding.

First 50 of 200 questions. Each one lists the choices, the correct answer, and an explanation. The checker at the top of this page saves progress in this browser when it is available.

Continue in the practice tool above to load more questions, 50 at a time.

Question 1Registration and Marketing Authorisation (MA)

Under the EU pharmaceutical legislation, which body is responsible for granting a centralised marketing authorisation for a medicinal product?

  1. The Heads of Medicines Agencies coordination group
  2. The European Directorate for the Quality of Medicines
  3. The European Commission acting on a CHMP opinion Correct answer.
  4. The national competent authority of the rapporteur member state

Explanation

The centralised procedure ends with a Commission decision; the EMA's Committee for Medicinal Products for Human Use provides the scientific opinion that underpins it. National authorities play no granting role in the centralised route. EDQM is a quality standards body, not a licensing authority.

Question 2Registration and Marketing Authorisation (MA)

A company wants one marketing authorisation valid across all EU member states for a new active substance for a chronic disease. Which application route fits?

  1. Mutual recognition procedure
  2. Centralised procedure Correct answer.
  3. Decentralised procedure
  4. National procedure

Explanation

New active substances for specified therapeutic areas, including diabetes, cancer and neurodegenerative disease, must use the centralised procedure, which yields a single EU-wide authorisation. The national, mutual recognition and decentralised routes all result in separate national authorisations.

Question 3Registration and Marketing Authorisation (MA)

The reference member state in the decentralised procedure is best described as the authority that:

  1. Performs all GMP inspections of the applicant's sites
  2. Collects all fees on behalf of the coordination group
  3. Issues the single EU-wide authorisation for the product
  4. Assesses the dossier and drafts the assessment report for the other states Correct answer.

Explanation

In the decentralised procedure the reference member state leads the scientific assessment and produces the draft assessment report, which concerned member states then review. It does not issue an EU-wide authorisation, because each state grants its own.

Question 4Registration and Marketing Authorisation (MA)

Which document must an applicant submit for a generic product to demonstrate that the reference product's safety and efficacy need not be re-established?

  1. A confirmatory clinical trial in the target population
  2. A new carcinogenicity study in two species
  3. A bioequivalence study report demonstrating equivalence to the reference product Correct answer.
  4. A full repeat of the reference product's phase III programme

Explanation

A generic application relies on the reference product's dossier, supported by bridging data such as bioequivalence. Repeating the full efficacy programme or adding new toxicology is not required for an abridged application.

Question 5Registration and Marketing Authorisation (MA)

A well-established medicinal use application must normally demonstrate that the substance has been in systematic medicinal use in the EU for at least:

  1. Fifteen years
  2. Ten years Correct answer.
  3. Five years
  4. Twenty years

Explanation

The well-established use route requires recognised efficacy and an acceptable safety level based on at least ten years of systematic and documented medicinal use within the EU. The ten-year period also aligns with the standard data exclusivity term.

Question 6Registration and Marketing Authorisation (MA)

Which of the following is a documentation requirement specific to a traditional herbal medicinal product registration?

  1. A full non-clinical safety package including carcinogenicity studies
  2. A paediatric investigation plan agreed with the committee
  3. A phase III randomised controlled trial in the proposed indication
  4. Bibliographic or expert evidence of at least 30 years of traditional medicinal use, 15 of them in the EU Correct answer.

Explanation

The traditional use registration relies on long-standing use evidence rather than new clinical trials: at least 30 years of use, with a minimum of 15 years within the EU. Full toxicology packages and efficacy trials are therefore not required for this route.

Question 7Registration and Marketing Authorisation (MA)

Which element is mandatory in the summary of product characteristics but not in the package leaflet?

  1. Instructions for use in the target population
  2. Advice on how to store the product
  3. The name and address of the marketing authorisation holder
  4. The pharmaceutical particulars including full qualitative and quantitative composition Correct answer.

Explanation

The SmPC is a professional document and must list the full qualitative and quantitative composition together with pharmaceutical particulars. The leaflet is written for patients and covers storage, holder details and instructions in lay language.

Question 8Registration and Marketing Authorisation (MA)

A marketing authorisation holder intends to change the manufacturer of the active substance. Which type of variation normally applies?

  1. Type II, a major variation requiring formal assessment
  2. Type IAIN, a notification requiring immediate notification before implementation Correct answer.
  3. Type IA, a do-and-tell notification
  4. Type IB, a minor variation requiring approval before implementation

Explanation

Replacing or adding an active substance manufacturer is a major quality change handled as a Type IAIN notification, which must be submitted immediately and before implementation. It is not a do-and-tell IA because it is not listed as a minor change of that class.

Question 9Registration and Marketing Authorisation (MA)

Which procedure is used to extend an existing national marketing authorisation to one or more additional member states?

  1. Decentralised procedure
  2. Mutual recognition procedure Correct answer.
  3. Centralised procedure
  4. National procedure

Explanation

The mutual recognition procedure takes an authorisation already granted by a reference member state and seeks recognition in further states. The decentralised procedure is used before any national authorisation exists, and the centralised and national routes do not extend existing authorisations.

Question 10Registration and Marketing Authorisation (MA)

In the centralised procedure, the initial evaluation of a new active substance application must be completed within:

  1. 120 days
  2. 210 days, excluding clock-stop periods Correct answer.
  3. 80 days
  4. 300 days

Explanation

The CHMP has 210 active assessment days, with the timetable paused whenever the applicant must answer questions. The clock-stop periods are not counted against that limit.

Question 11Registration and Marketing Authorisation (MA)

What is the standard period of regulatory data protection for a new active substance under EU law?

  1. Ten years from the date of submission
  2. Eight years from the date of the first marketing authorisation Correct answer.
  3. Five years from the date of the first marketing authorisation
  4. Twelve years from the date of submission

Explanation

The data exclusivity clock starts at the first EU authorisation and runs eight years, followed by a two-year market protection period. This forms the 8+2+1 structure, with the extra year available for a new therapeutic indication.

Question 12Registration and Marketing Authorisation (MA)

A generic applicant submits its application nine years after the reference product was first authorised in the EU. When may it be granted and marketed?

  1. It may be assessed now but marketed only after the ten-year market protection expires Correct answer.
  2. It may be granted and marketed immediately
  3. It must wait until twelve years have elapsed
  4. It may never rely on the reference product's data

Explanation

The generic application may be filed and assessed after the eight-year data exclusivity period, but the product cannot be placed on the market until the ten-year market protection ends. This is the practical effect of the 8+2 structure.

Question 13Registration and Marketing Authorisation (MA)

Which document defines the legal basis and conditions of a marketing authorisation and is the reference for subsequent variations?

  1. The risk management plan
  2. The good manufacturing practice certificate
  3. The periodic safety update report
  4. The marketing authorisation decision together with the approved summary of product characteristics Correct answer.

Explanation

The authorisation decision and the approved SmPC together set out the terms of the licence, and any change to those terms requires a variation. The other documents support pharmacovigilance or manufacturing compliance but do not define the licence conditions.

Question 14Registration and Marketing Authorisation (MA)

Which of the following products is excluded from the scope of the EU medicinal products directive by definition?

  1. A cosmetic product intended solely to cleanse the skin Correct answer.
  2. A vaccine for active immunisation
  3. A prescription-only oral anticoagulant
  4. A radiopharmaceutical for diagnosis

Explanation

Medicinal products are defined by presentation or function for treating or preventing disease. A product with no such claim and no pharmacological, immunological or metabolic action for a medical purpose, such as a purely cosmetic cleanser, falls outside the definition.

Question 15Registration and Marketing Authorisation (MA)

Which body performs the pharmacovigilance assessment of centrally authorised products and recommends regulatory action to the CHMP?

  1. The Pharmacovigilance Risk Assessment Committee Correct answer.
  2. The Committee for Advanced Therapies
  3. The Paediatric Committee
  4. The Committee for Orphan Medicinal Products

Explanation

PRAC is the EMA committee responsible for assessing and monitoring safety issues for human medicines and issuing recommendations. The other committees handle advanced therapies, paediatric plans and orphan designations respectively.

Question 16Registration and Marketing Authorisation (MA)

An application seeks orphan designation. Which criterion must the sponsor demonstrate?

  1. The product is the first of its class worldwide
  2. The product will be sold at a reduced price
  3. The condition affects no more than five in ten thousand people in the EU at the time of application Correct answer.
  4. The condition is life-threatening in all age groups

Explanation

Orphan designation requires a prevalence of no more than five per ten thousand in the EU, or that the product offers significant benefit where a satisfactory method exists. Severity and pricing are not the defining criteria.

Question 17Registration and Marketing Authorisation (MA)

Which type of application is required when a company seeks authorisation for a new indication for an already authorised product?

  1. A Type IA notification
  2. A Type IB variation
  3. A new centralised application
  4. A Type II variation Correct answer.

Explanation

Adding a therapeutic indication is a major change that requires a Type II variation with full assessment of the supporting data. It is not a minor change and does not require a fresh authorisation application.

Question 18Registration and Marketing Authorisation (MA)

The qualified person for pharmacovigilance of an EU marketing authorisation holder must be:

  1. A physician registered in any member state
  2. Resident in the country of the manufacturing site
  3. Permanently and continuously available and resident in the EU Correct answer.
  4. Employed by the national competent authority

Explanation

The QPPV must reside and operate in the EU and be continuously available for pharmacovigilance responsibilities. The role is held by the marketing authorisation holder's organisation, not by a regulator.

Question 19Registration and Marketing Authorisation (MA)

Which document must be submitted with an application to demonstrate that the applicant has systems in place to identify and prevent product shortages?

  1. A periodic safety update report
  2. A good clinical practice certificate
  3. A shortage prevention plan addressing supply and continuity Correct answer.
  4. A paediatric investigation plan

Explanation

Applicants must describe measures to ensure continued supply and prevent shortages, typically as a shortage prevention plan. The other documents address safety reporting, paediatric obligations and trial conduct.

Question 20Registration and Marketing Authorisation (MA)

Which is the correct description of a decentralised procedure application?

  1. It is assessed solely by the European Commission
  2. It applies only to generic products
  3. It extends a product already authorised in one member state to others
  4. It is submitted simultaneously to several member states for a product not yet authorised anywhere in the EU Correct answer.

Explanation

The decentralised procedure is used when no national authorisation yet exists and the applicant wants authorisations in several states at once, assessed by a reference member state. Mutual recognition, by contrast, extends an existing authorisation.

Question 21Registration and Marketing Authorisation (MA)

A company has an authorised product and wishes to change its pack size from 30 to 60 tablets. Which classification normally applies?

  1. Type II variation
  2. Type IB variation Correct answer.
  3. New marketing authorisation application
  4. Type IAIN notification

Explanation

A change in pack size within the approved range is a minor variation that requires assessment, so it is filed as Type IB. It does not affect the benefit-risk balance and does not need a new application.

Question 22Registration and Marketing Authorisation (MA)

Which requirement applies to the labelling of a medicinal product authorised in the EU?

  1. It must include the name and strength and the route of administration on the outer packaging Correct answer.
  2. It must be printed in English only
  3. It must omit the expiry date to avoid confusion
  4. It must list all excipients on the outer carton only

Explanation

Outer packaging must display key identifying information including the name, strength and route of administration, in the language of the member state where it is marketed. Excipients with known effect must be declared in the leaflet.

Question 23Registration and Marketing Authorisation (MA)

Which condition must be met before an application can rely on a reference product authorised in a third country rather than in the EU?

  1. The third-country product must be WHO prequalified
  2. The reference product must be authorised in the EU, so a third-country product cannot normally serve as the reference Correct answer.
  3. The third-country product must be manufactured in the EU
  4. The third-country product must be marketed for at least five years

Explanation

The abridged generic route requires comparison with a reference product authorised in the EU. A product authorised only outside the EU does not normally qualify, and WHO prequalification does not change that.

Question 24Registration and Marketing Authorisation (MA)

Which statement best describes the role of the coordination group in the mutual recognition and decentralised procedures?

  1. It conducts GMP inspections on behalf of all member states
  2. It resolves disagreements between member states that cannot be settled by the reference member state Correct answer.
  3. It sets the price of the product in each member state
  4. It grants the final EU-wide authorisation

Explanation

When concerned member states cannot agree, the matter is referred to the coordination group for resolution within a defined timetable. If consensus is not reached, it can be escalated to arbitration.

Question 25Registration and Marketing Authorisation (MA)

Which of the following is required to obtain an authorisation for a product containing a genetically modified organism?

  1. A separate application to the European Food Safety Authority
  2. A waiver from the centralised procedure
  3. An environmental risk assessment submitted with the application Correct answer.
  4. A mandatory clinical trial in healthy volunteers

Explanation

Applications for products containing GMOs must include an environmental risk assessment, which is assessed alongside the quality, safety and efficacy data. Consultation with other EU bodies may follow, but the ERA is the applicant's obligation.

Question 26Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Under the Pharmacy Board of the Philippines rules on licensure, which document primarily authorizes a registered pharmacist to lawfully practice the profession in the country?

  1. A barangay clearance for the pharmacy's business address
  2. A diploma in pharmacy countersigned by the dean
  3. A certificate of good standing from the Philippine Pharmacists Association
  4. A valid Certificate of Registration and Professional Identification Card issued by the PRC Correct answer.

Explanation

The PRC issues the Certificate of Registration and the Professional Identification Card, which together evidence the license to practice. Association membership and local clearances do not confer the legal right to practice. The diploma alone shows academic completion, not licensure.

Question 27Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which body is mandated to administer the pharmacist licensure examination and issue the professional license in the Philippines?

  1. The Philippine Pharmacists Association
  2. The Food and Drug Administration
  3. The Department of Health
  4. The Professional Regulation Commission Correct answer.

Explanation

The Professional Regulation Commission administers licensure examinations and issues professional licenses through its professional regulatory boards. The DOH and FDA regulate health services and products rather than individual professional licensure. The national association is a private professional organization.

Question 28Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacist wishes to renew a Professional Identification Card that lapsed two years ago. Which requirement is most consistent with PRC renewal rules?

  1. Resignation from any current pharmacy employment
  2. A new licensure examination in all subjects
  3. Endorsement by the employer's human resources office
  4. Submission of CPD credit units earned within the required period plus payment of renewal fees Correct answer.

Explanation

Renewal of the PIC requires compliance with the CPD requirement for the renewal period and payment of the prescribed fees. A lapsed card does not require retaking the full board examination. Employer endorsement and resignation are not renewal requirements.

Question 29Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

In the context of Philippine pharmacy law, what does the term 'continuing professional development' primarily refer to?

  1. The structured lifelong learning activities that maintain and enhance professional competence after licensure Correct answer.
  2. The internship hours completed before graduation
  3. The orientation given to newly hired pharmacy staff
  4. The annual audit of pharmacy financial records

Explanation

CPD covers structured learning activities that sustain and improve competence throughout a pharmacist's career after initial licensure. Pre-graduation internship and employer orientation are separate from CPD. Financial auditing is unrelated to professional development.

Question 30Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which of the following best describes a 'good pharmacy practice' principle in the dispensing process?

  1. Dispensing medicines without verifying the prescription to save time
  2. Confirming the prescription's legality and appropriateness before dispensing Correct answer.
  3. Storing prescription medicines on open shelves near the entrance
  4. Allowing unlicensed staff to counsel patients on prescription medicines

Explanation

Good pharmacy practice requires the pharmacist to verify that a prescription is valid and clinically appropriate before dispensing. Skipping verification, delegating counseling to unlicensed staff, and insecure storage all undermine patient safety.

Question 31Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacist is designing a CPD plan for the coming year. Which approach best reflects a self-directed, outcomes-based CPD framework?

  1. Identifying personal learning gaps and selecting activities that address them Correct answer.
  2. Attending only free seminars regardless of relevance to practice needs
  3. Completing all units in a single day before the deadline
  4. Collecting certificates without recording what was learned

Explanation

Outcomes-based CPD emphasizes identifying learning needs and choosing activities that address them, then reflecting on results. Merely accumulating certificates or rushing units ignores the purpose of competence development. Relevance to actual practice gaps is central.

Question 32Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which activity would most likely qualify as a formal CPD learning activity for a community pharmacist?

  1. Watching an unaccredited social media video
  2. Attending a friend's birthday celebration
  3. Reading a newspaper article about vitamins
  4. Accredited seminar on antimicrobial stewardship with an assessment Correct answer.

Explanation

Formal CPD activities are typically accredited, structured, and assessed, such as a seminar with a post-test. Informal or unaccredited material may supplement learning but generally does not count as formal CPD. Social and personal events are not CPD.

Question 33Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacy technician asks a pharmacist whether the technician may perform final verification of a dispensed prescription. What is the most appropriate response under good pharmacy practice?

  1. Yes, if the pharmacist is on a break
  2. No, because technicians are not allowed to handle medicines at all
  3. Yes, if the technician has several years of experience
  4. No, final verification and release require a licensed pharmacist Correct answer.

Explanation

Final verification and release of a dispensed medicine are professional functions reserved for a licensed pharmacist. Experience does not transfer this legal responsibility to a technician. Technicians may assist in preparation under supervision but cannot perform final checks.

Question 34Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which element is essential in a pharmacy's standard operating procedure for receiving and checking incoming medicine deliveries?

  1. Recording only the total number of boxes received
  2. Verification of supplier legitimacy, product identity, and expiry against the delivery documents Correct answer.
  3. Storing deliveries in the receiving area until month-end
  4. Accepting all deliveries without inspection during busy hours

Explanation

A receiving SOP must confirm that the supplier is authorized, that products match the order, and that expiry dates are acceptable. Skipping inspection or delaying storage risks counterfeit, damaged, or expired stock. Recording only box counts does not verify product identity.

Question 35Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which statement correctly describes the pharmacist's role in patient counseling under good pharmacy practice?

  1. Counseling may be replaced entirely by a package insert
  2. Counseling should be provided privately and documented where appropriate Correct answer.
  3. Counseling should be brief and avoid discussing side effects
  4. Counseling is optional and only done when the patient asks

Explanation

Good pharmacy practice expects counseling to be delivered in a manner that protects privacy and, where appropriate, documented. Counseling covers key points such as directions and side effects rather than avoiding them. A package insert supplements but does not replace pharmacist counseling.

Question 36Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacist moving to a new employer wants to confirm the status of their license. Which action best demonstrates compliance with licensure obligations?

  1. Assume the license remains valid because it was never revoked
  2. Verify the license status and renewal date with the PRC Correct answer.
  3. Postpone verification until an inspection occurs
  4. Rely on the employer to renew the license automatically

Explanation

Pharmacists are personally responsible for keeping their license current and can verify status and renewal dates with the PRC. Employers do not automatically renew professional licenses. Waiting for an inspection risks practicing on a lapsed license.

Question 37Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which of the following is a core component of a pharmacy's training program for new staff on good pharmacy practice?

  1. Training limited to operating the cash register
  2. Guidance to prioritize speed over accuracy
  3. Orientation on dispensing procedures, confidentiality, and error reporting Correct answer.
  4. Instruction to handle complaints without escalation

Explanation

A GPP-oriented training program covers dispensing procedures, patient confidentiality, and mechanisms for reporting errors and near misses. Training limited to cashiering or encouraging speed over accuracy neglects safety. Complaints should have an escalation pathway.

Question 38Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacist discovers a dispensing error that has already reached the patient. Which action best reflects good pharmacy practice?

  1. Document the error, inform the patient and prescriber, and take corrective action Correct answer.
  2. Discard the dispensing record to avoid liability
  3. Wait for the patient to report a problem before acting
  4. Conceal the error to protect the pharmacy's reputation

Explanation

Good pharmacy practice requires prompt disclosure, documentation, and corrective action when an error reaches a patient. Concealment or destroying records worsens harm and violates professional and legal obligations. Proactive communication with the patient and prescriber is essential.

Question 39Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which of the following best characterizes the purpose of accreditation of CPD providers?

  1. To limit CPD to a single professional organization
  2. To ensure learning activities meet quality standards and are relevant to practice Correct answer.
  3. To guarantee that all attendees will pass future examinations
  4. To replace the licensure requirement entirely

Explanation

Accreditation assures that CPD activities meet defined quality and relevance standards. It does not guarantee examination success, restrict CPD to one organization, or substitute for licensure. Quality assurance protects the value of CPD credits.

Question 40Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacist has earned more CPD units than the minimum required in a renewal period. What is the most accurate statement about excess units?

  1. Excess units are automatically void and cannot be used
  2. Excess units may be carried over only if the applicable rules allow it Correct answer.
  3. Excess units can be sold or transferred to another pharmacist
  4. Excess units replace the need for renewal fees

Explanation

Whether excess CPD units may be carried over depends on the applicable PRC and CPD council rules. Units are personal and cannot be sold or transferred. They never substitute for renewal fees.

Question 41Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which practice best supports the ethical principle of patient confidentiality in a community pharmacy?

  1. Sharing patient prescription details on social media
  2. Keeping patient records secured and limiting access to authorized staff Correct answer.
  3. Discussing a patient's medication in a crowded waiting area
  4. Leaving computer screens displaying patient data unattended

Explanation

Confidentiality requires securing records and restricting access to authorized personnel. Discussing medications publicly, posting details online, or leaving screens visible all breach patient privacy. Physical and digital safeguards are both necessary.

Question 42Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacist wants to verify that a CPD seminar's credits will be recognized before registering. Which factor is most important to check?

  1. Whether the activity carries valid accreditation from the appropriate CPD council Correct answer.
  2. Whether the venue is near the pharmacist's home
  3. Whether the speaker is a personal friend
  4. Whether the seminar includes free meals

Explanation

Recognition of CPD credits depends primarily on valid accreditation by the appropriate CPD council. Convenience, personal relationships, and catering do not determine credit validity. Checking accreditation before registering prevents wasted effort.

Question 43Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which of the following is most consistent with the pharmacist's duty when a prescription appears forged or altered?

  1. Alter the prescription to make it appear valid
  2. Clarify with the prescriber and withhold dispensing until verified Correct answer.
  3. Ignore the concern if the patient is a regular customer
  4. Dispense it immediately to avoid conflict with the patient

Explanation

When a prescription appears forged or altered, the pharmacist should verify with the prescriber and withhold dispensing until legitimacy is confirmed. Dispensing unverified prescriptions or altering them is unlawful. Regular customer status does not justify ignoring red flags.

Question 44Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which statement best describes the relationship between good pharmacy practice standards and pharmacy standard operating procedures?

  1. SOPs are unrelated to GPP and serve only administrative purposes
  2. GPP standards are optional while SOPs are mandatory
  3. SOPs replace the need for professional judgment
  4. SOPs translate GPP principles into specific, repeatable workplace steps Correct answer.

Explanation

SOPs operationalize GPP principles by defining specific, repeatable steps staff should follow. They do not replace professional judgment, nor are GPP standards optional. Administrative use alone understates their clinical and safety role.

Question 45Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

During a pharmacy inspection, the inspector asks for evidence of staff competence in handling refrigerated medicines. Which record best demonstrates this?

  1. A training log showing staff trained on cold-chain storage with temperature monitoring Correct answer.
  2. A menu of products sold
  3. A list of staff birthdays
  4. A copy of the pharmacy's business permit

Explanation

Evidence of competence in cold-chain handling is best shown by training records linked to temperature-monitoring procedures. Business permits and product menus do not demonstrate staff competence. Personal records are irrelevant to the inspection question.

Question 46Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which of these best reflects the principle of 'right patient, right medicine, right dose, right route, right time' in dispensing?

  1. Relying solely on the patient's verbal description of the medicine
  2. Checking patient identity and prescription details against the dispensed product before release Correct answer.
  3. Skipping the final check when the pharmacy is busy
  4. Dispensing the same product to all patients with similar symptoms

Explanation

The 'rights' of dispensing are upheld by systematically checking patient identity and prescription details against the prepared product before release. Uniform dispensing by symptom or skipping checks invites errors. Verbal descriptions alone are unreliable identifiers.

Question 47Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacist is asked to supervise a trainee during an internship rotation. Which supervisory practice best supports learning and patient safety?

  1. Allowing the trainee to perform pharmacist-only tasks unsupervised
  2. Providing structured tasks with progressive responsibility and direct oversight Correct answer.
  3. Assigning only clerical work for the entire rotation
  4. Leaving the trainee alone in the dispensary

Explanation

Effective supervision provides structured tasks with gradually increasing responsibility while maintaining direct oversight of pharmacist-only functions. Unsupervised performance of reserved tasks or leaving trainees alone endangers patients. Clerical-only work fails to develop competence.

Question 48Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which of the following best explains why CPD records should be maintained by the individual pharmacist?

  1. They are required only for pharmacists working abroad
  2. They are used to determine the pharmacist's salary
  3. They provide verifiable evidence of compliance and support reflective learning Correct answer.
  4. They replace the need for a valid license

Explanation

Personal CPD records provide verifiable evidence of compliance during renewal and support reflection on learning. They are not a substitute for licensure and are not tied to salary determination. The obligation applies broadly, not only abroad.

Question 49Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A patient asks for a prescription-only medicine without a prescription. What is the most appropriate pharmacist response under good pharmacy practice?

  1. Explain that a valid prescription is required and offer appropriate referral Correct answer.
  2. Substitute an unapproved product of unknown origin
  3. Dispense a partial dose without documentation
  4. Dispense it because the patient insists

Explanation

Prescription-only medicines require a valid prescription before dispensing. The pharmacist should explain the requirement and refer the patient appropriately. Yielding to insistence or dispensing undocumented partial doses violates the law. Unapproved products pose serious safety risks.

Question 50Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which statement best captures the pharmacist's continuing obligation after initial licensure?

  1. Delegating all learning to the employer
  2. Relying on licensure alone as proof of current competence
  3. Maintaining competence through ongoing learning and adherence to current practice standards Correct answer.
  4. Practicing exactly as learned in school without updating knowledge

Explanation

Licensure marks entry into practice, but pharmacists must maintain competence through ongoing learning and adherence to current standards. Relying on initial education or licensure alone leads to outdated practice. Learning responsibility is personal, not solely the employer's.